enrgy: zenocutuzumab in nrg1 fusion–positive tumors
Published 1 year ago • 157 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:56
enrgy: zenocutuzumab in nrg1 fusion-positive nsclc
-
0:46
enrgy: zenocutuzumab in nrg1 fusion-positive pancreatic ductal adenocarcinoma
-
4:03
phase i/ii trial of zenocutuzumab for tumors with nrg1 fusions
-
0:34
rational for her3-targeting in nrg1 fusion-positive nsclc
-
12:49
nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
-
9:16
behind the mystery: nrg1 fusions
-
2:45
dr. liu on nrg1 fusions in oncology
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
1:26
first line treatment of egfr mutation-positive nsclc
-
1:18
dr. tolba on targeting nrg1 fusions with afatinib
-
4:27
entrectinib: a review in ntrk solid tumours and ros1 nsclc
-
0:56
crizotinib for first line treatment of alk or ros1 rearrangements
-
1:49
a phase ii study of i-sabr in early or recurrent nsclc
-
0:51
assessing i-sabr in early or recurrent non-small cell lung cancer
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
1:15
dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
3:06
nice rejection of osimertinib: what does this mean for egfr nsclc in the uk?